Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. AmeriCann, Inc.
  6. News
  7. Summary
    ACAN   US0305881072

AMERICANN, INC.

(ACAN)
Delayed OTC Markets  -  12:45 2022-12-08 pm EST
0.1562 USD   -5.68%
10/19AmeriCann Generates All-Time Annual and Quarterly Revenue
GL
10/19Americann, Inc. Reports Sales Results for the Period Ended September 2022
CI
08/16AmeriCann Records Historic Quarterly Net Incomeáand Revenue
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Americann Inc : AmeriCann Comments on Newly Passed Federal Legislation

03/26/2018 | 08:31am EST

Omnibus Spending Bill Maintains Federal Protections for Cannabis Businesses

DENVER, CO / ACCESSWIRE / March 26, 2018 / AmeriCann, Inc. (OTCQB: ACAN), an Agricultural-Technology company that is developing the next generation of sustainable, state-of-the-art cannabis cultivation properties, medical cannabis cultivation properties discussed the recently enacted federal spending bill and its continued support of medical cannabis.

President Donald Trump on Friday signed a $1.3 trillion bill that includes a provision that prevents the Justice Department, including the Drug Enforcement Administration, from using funds to arrest or prosecute patients, caregivers, and businesses that are acting in compliance with state medical marijuana laws.

The provision, known as the Rohrabacher-Blumenauer Amendment, prohibits the Justice Department from using federal funds to interfere with state medical marijuana programs.

"The passage of this bi-partisan omnibus bill represents five consecutive years spanning two administrations that Congress has protected medical cannabis," stated Tim Keogh, President of AmeriCann. "This trend is very positive for the industry and reflects the overwhelming popularity and support for cannabis in the country."

Representative Earl Blumenauer said in a statement. "Poll after poll shows that the majority of Americans, across every party, strongly favor the right to use medical marijuana."

The provision that allows states to implement their own cannabis laws was first approved by the House in May 2014. The provision stems from an amendment originally sponsored by Rep. Dana Rohrabacher (R-CA) and former Rep. Sam Farr (D-CA).

About AmeriCann

AmeriCann (OTCQB: ACAN) is a publicly traded Agricultural Technology (Ag-Tech) company that is developing a new generation of sustainable, state-of-the-art medical cannabis cultivation and processing properties.

AmeriCann, Inc. is a Certified B Corp, an acknowledgment of the company's commitment to social and environmental ethics, transparency and accountability. AmeriCann became the first public cannabis company to earn this respected accreditation. More information about the Company is available at: www.americann.co, or follow AmeriCann on Twitter@ACANinfo.

About Massachusetts Medical Cannabis Center (MMCC)

The Massachusetts Medical Cannabis Center is approved for nearly 1,000,000 square feet of medical cannabis cultivation and processing in Freetown, Massachusetts. The state-of-the-art, sustainable, greenhouse project will consist of multiple planned phases for tenants in the Massachusetts medical marijuana market. Voters in Massachusetts approved legalizing the adult use of recreational marijuana in November of 2016. The state is on track to open the first cannabis storefronts for Adult-Use by July 1, 2018, making Massachusetts the first state in the Northeast to legalize cannabis.

AmeriCann's Cannopy System uniquely combines expertise from traditional horticulture, lean manufacturing, regulatory compliance and cannabis cultivation to create superior facilities and procedures. The company is planning to replicate the Canopy platform in additional states.

Image: https://www.accesswire.com/uploads/ACANN3_26_18.jpg

The first phase of the project consists of 160,000 sq. ft. of cultivation and processing infrastructure. AmeriCann can expand the first phase to approximately 600,000 sq. ft., based on patient demand.

About Solanna

AmeriCann has developed and owns "Solanna", a new comprehensive line of nutraceutical-grade cannabis-infused products. AmeriCann has created the brand, packaging concepts and invested significantly in Standard Operating Procedures and Good Manufacturing Practices to ensure safety, consistency, and efficacy across the product offering.

The intellectual property for Solanna will be licensed by AmeriCann to regulated cannabis businesses and will initially focus on providing healthier alternatives to smoking that include:

  • Capsules
  • Topical lotions and balms
  • Sublingual tinctures
  • Oral dissolving film
  • Trans-dermal applications

The Company plans to expand the product line to include edible products, health drinks, and branded concentrates. The products are designed to allow consumers to manage dosage through micro-dosing and to improve efficacy by incorporating blends of other plants, essential oils and other supplements that enhance and complement the benefits of cannabis.

The Solanna line of products will be offered exclusively through AmeriCann's Preferred Partners.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional uncertainties that could impact the Company's forward-looking statements, please see the Company's recently filed Registration Statement on Form S-1, which the Company has filed with the SEC and which may be viewed at www.sec.gov.

Contact Information:

Corporate:

AmeriCann, Inc.
3200 Brighton Blvd. Unit 114
Denver, CO 80216
(303) 862-9000
info@americann.co
www.americann.co
@ACANinfo on Twitter

Investors:
Hayden IR
hart@haydenir.com
(917) 658-7878

SOURCE: AmeriCann, Inc.


ę Accesswire 2018
All news about AMERICANN, INC.
10/19AmeriCann Generates All-Time Annual and Quarterly Revenue
GL
10/19Americann, Inc. Reports Sales Results for the Period Ended September 2022
CI
08/16AmeriCann Records Historic Quarterly Net Incomeáand Revenue
AQ
08/15AMERICANN, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
08/15AmeriCann, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Ju..
CI
07/12AmeriCann Announces All-Time Record Quarterly and Monthly Revenues
AQ
07/12AmeriCann, Inc. Reports Sales Results for the Month and Quarter Ended June 2022
CI
05/17AmeriCann Reports Positive Quarterly Financial Results and an Operations Update
AQ
05/16AMERICANN, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
05/16AmeriCann, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Ma..
CI
More news
Financials (USD)
Sales 2021 2,03 M - -
Net income 2021 -0,86 M - -
Net Debt 2021 8,50 M - -
P/E ratio 2021 -20,0x
Yield 2021 -
Capitalization 3,81 M 3,81 M -
EV / Sales 2020 38,6x
EV / Sales 2021 13,7x
Nbr of Employees 3
Free-Float 57,1%
Chart AMERICANN, INC.
Duration : Period :
AmeriCann, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Timothy Ryan Keogh Chief Executive Officer & Director
Benjamin J. Barton Director, Chief Financial & Accounting Officer
J. Tyler Opel Director
Sector and Competitors
1st jan.Capi. (M$)
AMERICANN, INC.-69.37%4
COLUMBIA CARE INC.-48.34%568
ASCEND WELLNESS HOLDINGS, INC.-75.64%304
ORGANIGRAM HOLDINGS INC.-40.99%303
AYR WELLNESS INC.-83.75%159
FLORA GROWTH CORP.-75.01%34